Toxoplasma gondii is an extremely successful opportunistic parasite which infects approximately one third of the human population worldwide. The impact of this parasite on human health becomes particularly manifest in congenital damage with infection and subsequent inflammation of neuronal tissues including the retina. Although advances in our understanding could be achieved in ocular toxoplasmosis, large gaps still exist on factors influencing the epidemiology and pathophysiology of this potentially blinding disease. We are only at the beginning of understanding the complex biology of this parasite and its mechanisms of invasion, virulence and interaction with the host's immune response. Since it is a preventable cause of blindness, it is necessary to assess factors that have the potential to control this disease in the future. This mini review will focus on recent advances in postnatal acquired ocular infection and the factors that may influence its prevalence and functional outcome.

Keywords:
Immunology, Ocular toxoplasmosis, Pathology, Toxoplasma gondii, Uveitis
1.
Holland GN: Ocular toxoplasmosis: a global reassessment. Part I. Epidemiology and course of disease. Am J Ophthalmol 2003;136:973-988.
2.
Kirby T: Calls for more detailed studies on toxoplasmosis. Lancet Infect Dis 2012;12:912-913.
3.
Dubey JP, Jones JL: Toxoplasma gondii infection in humans and animals in the United States. Int J Parasitol 2008;38:1257-1278.
4.
Kijlstra A, Jongert E: Toxoplasma-safe meat: close to reality? Trends Parasitol 2009;25:18-22.
5.
Hofhuis A, van Pelt W, van Duynhoven YT, Nijhuis CD, Mollema L, van der Klis FR, Havelaar AH, Kortbeek LM: Decreased prevalence and age-specific risk factors for Toxoplasma gondii IgG antibodies in the Netherlands between 1995/1996 and 2006/2007. Epidemiol Infect 2011;139:530-538.
6.
Nogareda F, Le Strat Y, Villena I, De Valk H, Goulet V: Incidence and prevalence of Toxoplasma gondii infection in women in France, 1980-2020: model-based estimation. Epidemiol Infect 2014;142:1661-1670.
7.
Tenter AM, Heckeroth AR, Weiss LM: Toxoplasma gondii: from animals to humans. Int J Parasitol 2000;30:1217-1258.
8.
Zhou DH, Zhao FR, Lu P, Xia HY, Xu MJ, Yuan LG, Yan C, Huang SY, Li SJ, Zhu XQ: Seroprevalence of Toxoplasma gondii infection in dairy cattle in southern China. Parasit Vectors 2012;5:48.
9.
Wu D, Lv R, Sun X, Shu F, Zhou Z, Nie K, Duan G, Zou F: Seroprevalence of Toxoplasma gondii antibodies from slaughter pigs in Chongqing, China. Trop Anim Health Prod 2012;44:685-687.
10.
Singh S, Khang TF, Andiappan H, Nissapatorn V, Subrayan V: An age-adjusted seroprevalence study of Toxoplasma antibody in a Malaysian ophthalmology unit. Trans R Soc Trop Med Hyg 2012;106:322-326.
11.
Dolgikh TI, Zaparii NS, Kadtsyna TV, Kalitin AV: Epidemiological and clinicoimmunological monitoring of toxoplasmosis in the Omsk region (in Russian). Med Parazitol (Mosk) 2008;1:19-22.
12.
Bowie WR, King AS, Werker DH, Isaac-Renton JL, Bell A, Eng SB, Marion SA: Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team. Lancet 1997;350:173-177.
13.
de Moura L, Bahia-Oliveira LM, Wada MY, Jones JL, Tuboi SH, Carmo EH, Ramalho WM, Camargo NJ, Trevisan R, Graca RM, da Silva AJ, Moura I, Dubey JP, Garrett DO: Waterborne toxoplasmosis, Brazil, from field to gene. Emerg Infect Dis 2006;12:326-329.
14.
Meerburg BG, Kijlstra A: Changing climate-changing pathogens: Toxoplasma gondii in North-Western Europe. Parasitol Res 2009;105:17-24.
15.
Jones JL, Dubey JP: Waterborne toxoplasmosis: recent developments. Exp Parasitol 2010;124:10-25.
16.
Feustel SM, Meissner M, Liesenfeld O: Toxoplasma gondii and the blood-brain barrier. Virulence 2012;3:182-192.
17.
Lachenmaier SM, Deli MA, Meissner M, Liesenfeld O: Intracellular transport of Toxoplasma gondii through the blood-brain barrier. J Neuroimmunol 2011;232:119-130.
18.
Courret N, Darche S, Sonigo P, Milon G, Buzoni-Gatel D, Tardieux I: CD11c- and CD11b-expressing mouse leukocytes transport single Toxoplasma gondii tachyzoites to the brain. Blood 2006;107:309-316.
19.
Blader IJ, Saeij JP: Communication between Toxoplasma gondii and its host: impact on parasite growth, development, immune evasion, and virulence. APMIS 2009;117:458-476.
20.
Sauer A, Rochet E, Lahmar I, Brunet J, Sabou M, Bourcier T, Candolfi E, Pfaff AW: The local immune response to intraocular Toxoplasma re-challenge: less pathology and better parasite control through Treg/Th1/Th2 induction. Int J Parasitol 2013;43:721-728.
21.
Guiton R, Vasseur V, Charron S, Arias MT, Van Langendonck N, Buzoni-Gatel D, Ryffel B, Dimier-Poisson I: Interleukin 17 receptor signaling is deleterious during Toxoplasma gondii infection in susceptible BL6 mice. J Infect Dis 2010;202:427-435.
22.
O'Connor W Jr, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, Kolls JK, Flavell RA: A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009;10:603-609.
23.
Sauer A, Pfaff AW, Villard O, Creuzot-Garcher C, Dalle F, Chiquet C, Pelloux H, Speeg-Schatz C, Gaucher D, Prevost G, Bourcier T, Candolfi E: Interleukin 17A as an effective target for anti-inflammatory and antiparasitic treatment of toxoplasmic uveitis. J Infect Dis 2012;206:1319-1329.
24.
Hu M, Zheng Q, Jia X, Li Y, Dong Y, Wang C, Lin Q, Zhang F, Zhao R, Xu H, Zhou J, Yuan H, Zhang W, Ren H: Neuroprotection effect of interleukin (IL)-17 secreted by reactive astrocytes is emerged from a high-level IL-17-containing environment during acute neuroinflammation. Clin Exp Immunol 2014;175:268-284.
25.
Sibley LD, Boothroyd JC: Virulent strains of Toxoplasma gondii comprise a single clonal lineage. Nature 1992;359:82-85.
26.
Dubremetz JF, Lebrun M: Virulence factors of Toxoplasma gondii. Microbes Infect 2012;14:1403-1410.
27.
Vallochi AL, Muccioli C, Martins MC, Silveira C, Belfort R Jr, Rizzo LV: The genotype of Toxoplasma gondii strains causing ocular toxoplasmosis in humans in Brazil. Am J Ophthalmol 2005;139:350-351.
28.
Grigg ME, Ganatra J, Boothroyd JC, Margolis TP: Unusual abundance of atypical strains associated with human ocular toxoplasmosis. J Infect Dis 2001;184:633-639.
29.
Su C, Khan A, Zhou P, Majumdar D, Ajzenberg D, Darde ML, Zhu XQ, Ajioka JW, Rosenthal BM, Dubey JP, Sibley LD: Globally diverse Toxoplasma gondii isolates comprise six major clades originating from a small number of distinct ancestral lineages. Proc Natl Acad Sci USA 2012;109:5844-5849.
30.
Herrmann DC, Barwald A, Maksimov A, Pantchev N, Vrhovec MG, Conraths FJ, Schares G: Toxoplasma gondii sexual cross in a single naturally infected feline host: generation of highly mouse-virulent and avirulent clones, genotypically different from clonal types I, II and III. Vet Res 2012;43:39.
31.
Kong JT, Grigg ME, Uyetake L, Parmley S, Boothroyd JC: Serotyping of Toxoplasma gondii infections in humans using synthetic peptides. J Infect Dis 2003;187:1484-1495.
32.
Peyron F, Lobry JR, Musset K, Ferrandiz J, Gomez-Marin JE, Petersen E, Meroni V, Rausher B, Mercier C, Picot S, Cesbron-Delauw MF: Serotyping of Toxoplasma gondii in chronically infected pregnant women: predominance of type II in Europe and types I and III in Colombia (South America). Microbes Infect 2006;8:2333-2340.
33.
Sousa S, Ajzenberg D, Vilanova M, Costa J, Darde ML: Use of GRA6-derived synthetic polymorphic peptides in an immunoenzymatic assay to serotype Toxoplasma gondii in human serum samples collected from three continents. Clin Vaccine Immunol 2008;15:1380-1386.
34.
Morisset S, Peyron F, Lobry JR, Garweg J, Ferrandiz J, Musset K, Gomez-Marin JE, de la Torre A, Demar M, Carme B, Mercier C, Garin JF, Cesbron-Delauw MF: Serotyping of Toxoplasma gondii: striking homogeneous pattern between symptomatic and asymptomatic infections within Europe and South America. Microbes Infect 2008;10:742-747.
35.
Maksimov P, Zerweck J, Maksimov A, Hotop A, Gross U, Pleyer U, Spekker K, Daubener W, Werdermann S, Niederstrasser O, Petri E, Mertens M, Ulrich RG, Conraths FJ, Schares G: Peptide microarray analysis of in silico-predicted epitopes for serological diagnosis of Toxoplasma gondii infection in humans. Clin Vaccine Immunol 2012;19:865-874.
36.
Shobab L, Pleyer U, Johnsen J, Metzner M, James ER, Torun N, Fay MP, Liesenfeld O, Grigg ME: Toxoplasma serotype is associated with development of ocular toxoplasmosis. J Infect Dis 2013;208:1520-1528.
37.
McLeod R, Boyer KM, Lee D, Mui E, Wroblewski K, Karrison T, Noble AG, Withers S, Swisher CN, Heydemann PT, Sautter M, Babiarz J, Rabiah P, Meier P, Grigg ME: Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009). Clin Infect Dis 2012;54:1595-1605.
38.
McLeod R, Brown C, Mack D: Immunogenetics influence outcome of Toxoplasma gondii infection. Res Immunol 1993;144:61-65.
39.
Mack DG, Johnson JJ, Roberts F, Roberts CW, Estes RG, David C, Grumet FC, McLeod R: HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol 1999;29:1351-1358.
40.
Bhongsatiern J, Ohtsuki S, Tachikawa M, Hori S, Terasaki T: Retinal-specific ATP-binding cassette transporter (ABCR/ABCA4) is expressed at the choroid plexus in rat brain. J Neurochem 2005;92:1277-1280.
41.
Jamieson SE, de Roubaix LA, Cortina-Borja M, et al: Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS One 2008;3:e2285.
42.
Peixoto-Rangel AL, Miller EN, Castellucci L, Jamieson SE, Peixe RG, Elias Lde S, Correa-Oliveira R, Bahia-Oliveira LM, Blackwell JM: Candidate gene analysis of ocular toxoplasmosis in Brazil: evidence for a role for toll-like receptor 9 (TLR9). Mem Inst Oswaldo Cruz 2009;104:1187-1190.
43.
Albuquerque MC, Aleixo AL, Benchimol EI, Leandro AC, das Neves LB, Vicente RT, Bonecini-Almeida Mda G, Amendoeira MR: The IFN-γ +874T/A gene polymorphism is associated with retinochoroiditis toxoplasmosis susceptibility. Mem Inst Oswaldo Cruz 2009;104:451-455.
44.
Cordeiro CA, Moreira PR, Bessa TF, Costa GC, Dutra WO, Campos WR, Orefice F, Young LH, Teixeira AL: Interleukin-6 gene polymorphism (-174 G/C) is associated with toxoplasmic retinochoroiditis. Acta Ophthalmol 2013;91:e311-e314.
45.
Shaw MH, Reimer T, Sanchez-Valdepenas C, Warner N, Kim YG, Fresno M, Nunez G: T cell-intrinsic role of Nod2 in promoting type 1 immunity to Toxoplasma gondii. Nat Immunol 2009;10:1267-1274.
46.
Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, Rothova A: Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology 2002;109:869-878.
47.
Holland GN, Crespi CM, ten Dam-van Loon N, Charonis AC, Yu F, Bosch-Driessen LH, Rothova A: Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. Am J Ophthalmol 2008;145:1007-1013.
48.
de-la-Torre A, Rios-Cadavid AC, Cardozo-Garcia CM, Gomez-Marin JE: Frequency and factors associated with recurrences of ocular toxoplasmosis in a referral centre in Colombia. Br J Ophthalmol 2009;93:1001-1004.
49.
Garweg JG, Scherrer JN, Halberstadt M: Recurrence characteristics in European patients with ocular toxoplasmosis. Br J Ophthalmol 2008;92:1253-1256.
50.
Garweg JG, Scherrer J, Wallon M, Kodjikian L, Peyron F: Reactivation of ocular toxoplasmosis during pregnancy. BJOG 2005;112:241-242.
51.
O'Connor GR: Factors related to the initiation and recurrence of uveitis. XL Edward Jackson memorial lecture. Am J Ophthalmol 1983;96:577-599.
52.
Mänz M, Schlüter D, Liesenfeld O, Schares G, Gross U, Pleyer U: Ocular toxoplasmosis past, present and new aspects of an old disease. Prog Retin Eye Res 2014;39:77-106.
53.
Silva AC, Rodrigues BS, Micheletti AM, Tostes S Jr, Meneses AC, Silva-Vergara ML, Adad SJ: Neuropathology of AIDS: an autopsy review of 284 cases from Brazil comparing the findings pre- and post-HAART (highly active antiretroviral therapy) and pre- and postmortem correlation. AIDS Res Treat 2012;2012:186850.
54.
Weiss LM, Dubey JP: Toxoplasmosis: a history of clinical observations. Int J Parasitol 2009;39:895-901.
55.
Thoden J, Potthoff A, Bogner JR, et al: Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066). Infection 2013;41(suppl 2):S91-S115.
56.
Chung H, Kim JG, Choi SH, Lee SY, Yoon YH: Bilateral toxoplasma retinochoroiditis simulating cytomegalovirus retinitis in an allogeneic bone marrow transplant patient. Korean J Ophthalmol 2008;22:197-200.
57.
Edvinsson B, Lundquist J, Ljungman P, Ringden O, Evengard B: A prospective study of diagnosis of Toxoplasma gondii infection after bone marrow transplantation. APMIS 2008;116:345-351.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.